In an attempt to curb the harrowing opioid crisis in America, drugmakers have developed what they tout as “abuse-deterrent” pain-killers – opioid formulations that are designed to prevent users from injecting the drugs.
But a report published this week by the Institute of Clinical and Economic Review found that there isn’t enough evidence to claim that these re-formulated drugs effectively reduce abuse and that the price of abuse-deterrent opioids is a barrier for large-scale adoption.
Get the full story at our sister site, Drug Delivery Business News.
The post Study: Abuse-deterrent opioids are costly and unproven appeared first on MassDevice.